The biopharmaceutical industry is undergoing significant digital transformation. While this shift brings exciting opportunities, it also introduces increasing complexity and growing expectations ...

The company, whose headquarters is on Innovation Way, Heslington, has also finalised a royalty agreement with its development partner, Neuro-Bio Ltd. Under the agreed terms, Aptamer is eligible to ...

Last year, during the Global Synthetic Biology (SynBioBeta) conference, Ansa Biotechnologies’ CEO Jason Gammack introduced attendees to the company’s first product—600 bp synthetic DNA ...

Is Adaptive Biotechnologies (ADPT) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer ...

--(BUSINESS WIRE)--#AnsaOnTimeGuarantee--Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program, providing ...

New workflow combines Mission Bio’s Tapestri ® Platform and Integrated DNA Technologies’ (IDT) rhAmpSeq™ capabilities to demonstrate potential for a cost-effective, scalable, and highly customizable ...

EMERYVILLE, Calif., May 06, 2025--(BUSINESS WIRE)--Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program ...

A week ago, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenue crushed ...